

Subject Index to Volume 4 (1987)

- absorption, 271
 - oral, 120
- acyclovir, 200
- adsorptiochromism, 398
- adsorption of inorganic ions, 244
- adsorption of organic ions, 244
- aging, accumulation of modified proteins, 278
- alimentary tract, lipoidal permeability barriers, 271
- amide hydrolysis, 42
- amiodarone, 251
- analgesic agents, physical properties, 255
- analgesics, 321
- analysis of peptides, 5
- analysis of plasma, 28
- analysis of proteins, 5
- analysis, automated segmented continuous flow, 54
- analysis, system, 86
- analysis, thermogravimetric, 133
- angiotensin-converting enzyme inhibition, 364
- angiotensin-converting enzyme inhibitor degradation, 392
 - epimerization, 392
 - formation, 392
 - hydrolysis, 392
- antagonists, opioid, 147
- anti-ulcer agents, 171
- antibiotic degradation, 214
- antibiotics, 137
- anticonvulsants, 321
- antifungal agents, 321
- antifungal oxoaporphine alkaloids, 495
- antihypertensives, 364
- antiinflammatory agents, physical properties, 255
- antimalarial artemisinin, 258
- antimalarial, Chinese medicinal herbes, 258
- antimitotic agents, 162
- antineoplastic agents, 509
- antipyrene pharmacokinetics, 251
- antipyrene pharmacokinetics, effects of hydralazine, 515
- antispasmodic activity, 166
- antiviral activity, 200
- antiviral agents, 120
- aqueous stability, 42
- Arrhenius expressions for hydrolysis reactions, 342
- Artemisia annua*, 258
- artemisinin, 258
- aspirin, 255
- assay, stability indicating, 38, 54
- assays, receptor binding, 154
- atomic absorption spectrophotometry, graphite furnace, 332
- automated analysis, segmented continuous flow, 54
- automated sample preparation, 54
- azone, elimination, 519
 - in vitro* studies in humans, 519
 - percutaneous absorption, 519
- BW755C, inhibitor of arachidonate metabolism, 527
- Bacillus stearothermophilus*, 154
- bacteriocidal action of neutrophils, 278
- basic amine drugs, 142
- basic drugs, subcellular distribution, 50
- benzocaine solubility, 220, 231
- benzyl alcohol, 38
- bile and systemic drug availability, 195
- binding sites for basic drugs, 142
- bioadhesion, 457
- bioavailability, 150, 536
 - between-lot/within-lot, 499
 - equation for systemic drug, 195
 - of ibuprofen, 486
 - percutaneous, 265
 - variability, 536
- biodegradable drug delivery systems, 465
- bioequivalence, 150
 - percutaneous, 265
- biotechnology, perspective of PMA, 361
- biotin, assay in multivitamin-multimineral, 261
- bis(helenaliny)malonate, 509
- body temperature, 113
- brain, 16
- brush border, lipid composition, 271
- bumetanide, acute tolerance, 379
 - pharmacodynamics, 379
 - pharmacokinetics, 379
- calcium channel antagonist, gallopamil, 327
 - verapamil, 327
- calcium channel blockers, 166
- cancer immunotherapy, 181
- cancer treatment, 181
- candidiasis, disseminated, 495
- captopril disulfide, 98
- captopril oxidation, 98
- captopril stability, 98
- catecholamines, 16
- cefixime, 33
- cellulose acetate phthalate, 70
- central nervous system, 130
- cephalosporin, 33
 - aminolysis, 214
 - zinc mediated degradation, 214
- ceramides, 271
- Chinese herbal medications, 126
- Chinese medicinal herbs, antimalarial, 258
- chiral mobile-phase additives, 285
- chiral separations, 285
- chiral stationary phases, 285
- cholesterol, 21, 472
- Chuifong toukuwan, 126
- ciliary movement, 445
- ciliostimulants, 445
- ciliotoxicity, 445
- cimetidine, quantitative determination, 133
- clastic binding hypotheses, 450
- clozapine, multiple dose pharmacokinetics, 402
- combination diuretic products, 348
- computer simulation, 385
- computer-designed formulation, 311
- concomitant drug administration, 433
- conflict of interest, 83
- congestive heart failure, treatment, 364
- content uniformity, 54
- contraceptive steroids, depressant activity of ethanol, 240
- controlled-release dosage forms, 75
- controlled-release pellet formulation, 480
- controlled-release theophylline, 416
- controlled-release oral formulations, 86
- coronary thrombosis, 375
- cosolvency, 200, 231
- crypt cells, intestinal epithelial, 425
- crystal changes, 231
- crystalline solids, 104
- cyclic imides, 21

- cytidine, high dose, 113
cytotoxic agents, bis(helenalinyl)malonate, 509
 helenalin, 509
- DHPG, 9-[(1,3-dihydroxy-2-propoxy)-methyl]guanine, 120
decarboxylation, solid state, 137
degradation of microcapsules, 62
deliquescence, 104
5'-deoxy-5'-fluorouridine, phosphorylase inhibitor, 425
dermal allergens, iontophoretic electrode material, 438
dermal delivery, 317
desethylaminodarone, 251
dexamethasone, therapeutic agent for T-2 toxicosis, 527
diastereomeric derivatization, 285
diazepam solubility, 220, 231
differential scanning calorimetry, 429
diffusion cell, flow through, validation, 337
 transdermal research, 337
diffusion cells, 317
dihydrouracil, 113
diketopiperazine, 392
dimethylsulfoxide, as penetration enhancer, 436
diseases, premature aging, 278
disintegration time, effect of stable isotope incorporation, 524
dissolution, 150
 in vitro statistical analysis, 416
dithiazoles, antifungal activity, 321
 insecticidal activity, 321
 synthesis, 321
dithiobiurets, analgesic activity, 321
 anticonvulsant activity, 321
 antifungal activity, 321
 insecticidal activity, 321
 synthesis, 321
diuretics, antikaliuretic response, 66
 natrietic response, 66
 pharmacodynamics, 66
 site of action, 66
dopamine, 16
dosage form design, computer aided, 385
 prolonged action, 311
droplet interactions, 301
drug absorption, 248
 gastrointestinal, 481
drug administration, concomitant, 433
drug binding to lung mitochondria, 142
drug delivery, 3
drug delivery systems, 181, 311
drug delivery systems, sustained release, 385
drug delivery, biodegradable system, 465
 targeted, 3, 181
drug disposition, nonlinear, moment analysis, 59
drug impurity limit testing, 177
drug interactions, 240, 251, 433
drug metabolism, 433, 515
drug potency, 177
drug release from tableted microcapsules, 70
 from tablets, 70
 in vitro, 70
 numerical deconvolution, 480
drug shelf life, 177
drug stability testing methods, 177
 reaction, mechanisms, 177
drug-receptor interactions, 450
drugs, basic, 50
 basic amine, 142
Dyazide, absorption, 348
- elastomers, analysis of, 237
electron and charge transfer, 450
emulsions, water soluble, 162
emulsion sizing, 301
enantiomeric resolution, 285
endorphins, 147
enteric-coated granules, 70
enterohepatic recirculation, 195
enzyme inhibitors, 364
epinephrine, 158
ethanolamines, pharmacology, 166
 synthesis, 166
ethinyl estradiol, 54, 240
2-ethyl-1,3-hexanediol, as penetration enhancer, 436
etintidine, 133
 plasma determination, 133
etretinate, dose proportionality, 420
 pharmacokinetics, 420
expression vector system, 92
fast atom bombardment, 5
fentanyl metabolism, 46
fiber-optic Doppler anemometry, emulsion sizing, 301
first pass metabolism and systemic drug availability equation, 195
flucinolone acetinide degradation in topical cream, 342
 pH dependence, 342
 temperature dependence, 342
flucinolone acetone stability, 342
5-fluorouracil, phosphorylase inhibitor, 425
food-drug interactions, 348
food-formulation interactions, 348
formaldehyde, model for aldehydes in foods, 158
formulating flexibility, maximum, 311
formulation, computer designed, 311
 controlled release pellets, 480
 multidose injection, 38
formulations, long-acting, 311
foscarnet, 200
fosfomycin, 255
fractionation, subcellular, 50
Franz cell, performance comparison to flow through cell, 337
furosemide adsorption, 171
furosemide bioavailability, 150, 171
furosemide bioequivalence, 150
furosemide diuretic effect, 171
- gallbladder emptying and systemic drug availability equation, 189
gallopamil, calcium channel antagonist, 327
gastric emptying, 78
gastric retention time, 457
gastrointestinal drug absorption, 480
gastrointestinal transit, 78
 ibuprofen, 486
gastrointestinal transit time, 480
Gliocladium roseum, 353
glycolipids, 271
gold, 332
gold sodium thiomalate, bioavailability, 332
 intramuscular, 332
 intravenous, 332
 pharmacokinetics, 332
graphite furnace atomic absorption spectrophotometry, 332
- HPLC, automated stability indicating, 54
 enantiomeric resolution, 285
 microassay for etintidine, 133
 morphine metabolites, 46
 of human plasma, 327
 progabide metabolites, 28
 reversed phase, 28
 stability indicating assay, 38
 with fluorescence for gallopamil, 327
 with fluorescence for norgallopamil, 327
hallucinogen receptors, 450
haptens, properties, 207
 synthesis, 207
helenalin, 509
hepatic drug metabolism, 251
hepatic extraction and systemic drug availability equation, 195
herbal medications, adulterated with prescription drugs, 126
herpes encephalitis, experimental, 200
herpes simplex virus type 2, 200
high density lipoprotein cholesterol, 472

- high dose cytidine, 113
 high dose uridine, 113
 human serum, assay for opiate narcotics in, 46
 hydralazine, concomitant absorption with metoprolol, 515
 concomitant absorption with propranolol, 515
 hydralazine, oral bioavailability, 515
 hydrochlorothiazide, absorption, 348
 in Chinese herbal medicine, 126
 hydrogels, poly(acrylic acid), 457
 hydrogen bonding, cosolvents, 220
 hydrolytic degradation, poly(L-lactide)microcapsules, 62
 hydroxyphenethylamines, 158
 hydroxyurea, quantitative NMR, 412
 hygroscopicity, salts of analgesic/antiinflammatory agents, 255
 hypnotics, 321
 hypolipidemic agents, *in vivo* synthesis and activity, 21
 phthalimide derivatives, 472
 hypothermia, effect on drug absorption, 248
- ibuprofen, bioavailability, 486
 gastrointestinal transit, 486
 ileum, drug effects, 147
 3-imino-1-oxoisindoline synthesis, 21
 imipramine, binding in lung mitochondria, 50
 immunoconjugates, targeted drug delivery, 181
 immunotherapy, cancer, 181
in vivo pharmacology, application of kinetic effect models to, 86
 indomethacin, in Chinese herbal medicines, 126
 industrial-university partnerships, 83
 infectious disease, prophylaxis, 92
 infrared spectroscopy, oxonicotinic acid, 429
 injection, determination of TRH in multidose, 38
 insectidal activity of thiobiurets and thiazoles, 321
 insulin, mouse bioassay for, 189
 insulin formulation, radioreceptor assay, 189
 intersubject variability, furosemide, 150, 536
 intestinal elimination, and systemic drug availability equation, 189
 intestinal epithelial crypt cells, 425
 intestinal phosphorylases, inhibition, 425
 intramuscular injectables, tissue tolerance, 486
 intravenous lipid emulsion, 301
 intrinsic dissolution, rate of THAM salt, 255
 5-iodo-2'-dioxycytidine, 317
 iontophoresis, electrode material as dermal allergens, 438
 ischemia, and PGB_x therapy, 130
 isodithiobiurets, antifungal activity, 321
 insecticidal activity, 321
 synthesis, 321
 isosorbide-5-nitrate, absorption rate, 480
 isothiodiurets, analgesic activity, 321
 anticonvulsant activity, 321
- KB carcinoma cells, 509
 kinetic-effect model (KEM) applications, 86
 kinetics of oxidation of ACE inhibitors, 98
 kyotorphin synthesis, 154
- l-norgestrel-ethinyl estradiol tablets, 54
 lidocaine degradation kinetics, 42
 lipid solubility, subcellular binding of basic drugs, 142
 subcellular distribution of basic drugs, 50
 lipids, permeability barriers in skin and alimentary tract, 271
 lipoproteins, effects of oxoisindolines, 21
 liposomes, 181
 liquid-solid extraction, etintidine, 133
 liriodenine, 495
 liriodenine methiodide, 495
 log-linear solubility equation, 220
 deviations, 231
 lung, 50
 lung mitochondria, drug binding, 142
- mass spectrometry, 5, 126
 mean residence time, 59
 membrane lipids, 271
- mesoridazine, 207
 metaproterenol, 158
 metaraminol, 158
 metoclopramide, 50
 Michaelis-Menten elimination, 59
 microencapsulation, 70
 microsphere surface layer structure, drug release, 465
 microspheres, poly(dl-lactide), 465
 mitochondria, 50, 142
 mitomycin C-dextran conjugate, antitumor activity, 293
 physicochemical properties, 293
 polymeric prodrug, 293
 tissue distribution, 293
 mixed-function oxidase (MFO) systems, 278
 modeling, pharmacokinetic-pharmacodynamic, 86
 models, kinetic-effect, 86
 one-compartment, 59
 Moduretic, absorption, 348
 molecular mechanics calculations, 137
 moment analysis, nonlinear drug disposition, 59
 monoamine oxidase inhibitors, 16
 monoclonal antibodies, 181
 morphine metabolism, 46
 mouse bioassay, insulin, 189
 moxalactam, decarboxylation, 137
 mucoadhesion, hydrogen binding, 457
 multidose injection, 38
 multiple dose pharmacokinetics, 402
 mycotoxins, T-2, 527
- N-(2-cyanoethyl)tranylcypromine, 16
 N-Mannich-base prodrugs, 317
 N-alkyl-1,2-diphenylethanolamines pharmacology, 166
 synthesis, 166
 N-desmethyltamoxifen, 353
 naloxone, 147
 naloxone estrone azine, 147
 naltrexone, narcotic antagonist, 305
 narcotic antagonists, 305
 nasal drug delivery, 445
 natriuresis, potassium induced, 531
 neurological dysfunction, 130
 neuropeptides, 92
 neurotransmitter amines, 16
 neurotransmitters, 16
 neutron activation, barium 138, 524
 erbium, 170, 524
 radiolabeling, 486
 radiolabeling of intact tablets, 524
 samarium 152, 524
 neutrophils, bacteriocidal action, 278
 nitrofurantoin macrocrystals, bioavailability, 499
 drug absorption, 499
 urinary excretion, 499
 nitroglycerin, penetration enhancers, 436
 transdermal delivery, 436
 nonsteroidal antiestrogens, 353
 noradrenaline, 16
 norethindrone, 240
 nuclear magnetic resonance spectroscopy, 412
 nucleic acid inhibition, 509
 numerical deconvolution, 480
- o-(N-phthalimide)acetophenone, hypolipemic action, 472
 oleic acid, as penetration enhancer, 436
 oligopeptides, radioisotope-labeled assays, 154
 one-compartment model, 59
 opiate narcotics, 46
 opiate receptors, 450
 opioid antagonists, 147
 opioid receptors, 147
 optical isomers, separation, 285
 oral absorption, 120
 oral cephalosporin, 33
 oral contraceptive tablets, 54

- oral controlled-release formulations, 86
- oxidation, cupric ion catalyzed, 98
- oxidation kinetics, 98
- oxoaporphine alkaloids, 495
- oxoglucine methiodide, 495
- oxonicotinic acid, phase transition, 429
 - polymorphic quantitation, 429
 - polymorphism, 429
- PHPG polymeric backbone, 305
- PMA perspective on biotechnology, 361
- paralysis, 130
- pellet density, 78
- penetration enhancer, azone, 519
- penetration enhancers, 436
- pentobarbital, 248
- pentobarbitone, hypnotic effect, 321
- pentoxifylline, common metabolic pathway with theophylline, 433
 - pharmacokinetics, 433
- pentylene-tetrazole convulsion inhibition, 406
- peptide analysis, 5
- peptide drugs, 364
- peptide synthesis, 154
- percutaneous absorption of azone, 519
- percutaneous penetration studies, 265
- pharmacodynamics, 66
- pharmacokinetic-pharmacodynamic modeling, 86
- pharmacokinetics, 3, 59
 - dose-dependent, 33
 - gold sodium thiomalate, 332
 - multiple dose, 402
 - systemic drug availability equation, 195
 - theophylline, 385
- pharmacology, *in vivo*, 86
- phenethylamines, pharmacology, 166
- phenethylamines, synthesis, 166
- phenolic antioxidants, 237
- phenolic cyclization, pharmaceutical implications, 158
 - rates, 158
- phenylephrine, 158
- phenytoin solubility, 220, 231
- plasma analysis, 28
- plasma enzyme activities, 487
- plasma proteins as degradation catalysts, 62
- plasminogen activators, 375
- poly(L-lactide) microcapsules, degradation properties, 62
- poly(L-lactide) solubility, 62
- poly(α -amino acid) backbones, biodegradable, 305
- poly(acrylic acid) hydrogels, 457
- poly(dl-lactide) microspheres, water soluble drug entrapment, 465
- polycarboxylic adsorption of ions, 244
- polymeric backbones, 305
- potassium chloride, bioavailability, 409
 - pharmacokinetics, 409
 - sustained release tablets, 409
- potassium induced natriuresis, 531
- potassium pharmacokinetics, 531
- potassium retaining drugs, 66
- premature aging diseases, 278
- prodrug, 16
- prodrug derivatives, 120
- progabide, 28
- prophylaxis of infectious disease, 92
- prostaglandin, increased by mycotoxins, 527
- prostaglandin D₂, 406
- prostaglandin F_{2 α} , 255
- prostaglandins, 130
- protein analysis, 5
- protein binding, concentration dependent, 33
- protein degradation, 278
- protein oxidation, mechanisms, 278
- protein processing, 92
- proteins, plasma, 62
- pteridine derivatives as potassium retaining drugs, 66
- pyrimidine nucleoside phosphorylases, inhibition, 425
- pyrimidine nucleosides as thermoregulators, 113
- quantitative NMR for urea, 412
- quinine, 50
- rabbit model, pharmacokinetic, 332
- radioimmunoassay (RIA), 46
 - mesoridazine, 207
 - sulforidazine, 207
 - thioridazine, 207
- radiolabeling, intact by neutron activation, 486
 - neutron activation, 524
- radioreceptor assay (RRA), 46
 - insulin, 189
- rat liver membranes, 189
- receptor binding assays, 154
- receptors, opioid, 147
- recombinant vaccines, 92
- renin inhibitors, 364
- renin-angiotensin system, 364
- salt selection, 255
- scintigraphy, gamma, 480, 486
- serotonin-mediated convulsion inhibition, 406
- silica surface polarity, 398
- skin, diffusion cell experiments, 317
- skin, lipoidal permeability barriers, 271
- sodium chloride, 104
- sodium salicylate, 104
- solid dosage forms, intestinal transit, 78
- solid extraction, 137
- solid-state decarboxylation, 137
- solubility equation, log-linear, 220
- solubility estimation, 220
- solubility, lipids, 50, 142
- solvatochromism, 398
- solvent evaporation method, 465
- solvent mixtures, 231
- solvent polarity, 220
- spectrophotometry, graphite furnace atomic absorption, 332
- spinal cord injury, ischemic, 130
- spiropyran, 398
- stability assay, decomposition products, 177
- stability indicating assay, 38, 54, 177
- stability tests, initial-rate method, 177
- stability, aqueous, 42
- steroid formulation, 342
- steroids, 147
- stochastic control, 86
- stratum corneum, lipid composition, 271
- subcellular fractionation, 50
- subcutaneous sarcoma 180, 293
- sucalfate, absorption of administered drugs, 171
- sulfamethoxazole, 70
- sulforidazine, 207
- surface dissolution, 104
- suspension spectra, 398
- sustained release, 70, 385
- sustained release dosage formulation, 244
- sustained release tablet, intact radiolabeling, 486
- system analysis, 86
- tablet excipients, particle size determination, 504
- tablet hardness, effect of stable isotope incorporations, 524
- tablets, whole vs. half, 416
- tamoxifen *Gliocladium roseum*, 353
 - microbial metabolism, 353
 - resistance to biotransformation, 353
- tamoxifen metabolites, antiestrogenic properties, 353
 - estrogenic properties, 353
- tamoxifen N-oxide, 353
- targeted drug delivery, 181
- taxol, formulation, 162
- terbutaline, 158
- tetrahydroisoquinolines, 158

- theophylline, common metabolic pathway with pentoxifylline, 433
- pharmacokinetics, 433
- theophylline delivery systems, computer simulations, 311
- steady-state plasma concentration, 311
- theophylline pharmacokinetics, 385
- thermal microscopy, 429
- thermogravimetric analysis, 137
- thermoregulation, 113
- thiazoles, 321
- thin-layer chromatography, 237
- thiobiurets, 321
- thiol, 98
- thioridazine, 207
- thrombolytic therapy, 375
- thymidine, phosphorylase inhibitor, 425
- thyrotropin releasing hormone (TRH), 38
- tissue plasminogen activator, recombinant, 375
- tissue tolerance of intramuscular injectables, 486
- topical delivery enhancers, 317
- toxicity of triacetin, 162
- toxol-triacetin emulsion, 162
- transdermal delivery, penetration enhancers, 436
- transdermal diffusion cells, 337
- transit time, gastrointestinal, 480
- tranlycypromine, 16
- triacetin toxicity, 162
- triamterene derivatives, 66
- tricholthecene, 527
- triglycerides, 21
- triglycerides, de novo synthesis, 472
- trimterene, absorption, 348
- tris(hydroxymethyl)aminomethane (THAM) salts, 255
- tumor localization, 293
- tumor therapy, 181
- tyrosyl-tRNA synthetase, 154
- ulcer treatment, 171
- university-industrial partnerships, 83
- uracil, phosphorylase inhibitor, 425
- urea, 62
- quantitative NMR, 412
- uridine, high dose, 113
- phosphorylase inhibitor, 425
- uridine catabolites, 113
- uridine pharmacokinetics, 113
- vaccines, recombinant, 92
- vaccinia virus, 92
- VaraU, 200
- variability 75/75 rule, 536
- vas deferens, drug effects, 147
- verapamil, calcium channel antagonist, 327
- video recording, particle size determination, 504
- 5-vinyl-1- β -D-arabinofuranosyluracil (VaraU), 200
- Water soluble drugs in microspheres, 465
- water structure, 231
- water vapor sorption, 104
- x-ray crystallography, 133
- x-ray diffraction, 429
- zero-order delivery, 385
- zinc ion mediated degradation, 214
- zomepirac, 255